195 related articles for article (PubMed ID: 36917021)
21. Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes.
Durinck S; Stawiski EW; Pavía-Jiménez A; Modrusan Z; Kapur P; Jaiswal BS; Zhang N; Toffessi-Tcheuyap V; Nguyen TT; Pahuja KB; Chen YJ; Saleem S; Chaudhuri S; Heldens S; Jackson M; Peña-Llopis S; Guillory J; Toy K; Ha C; Harris CJ; Holloman E; Hill HM; Stinson J; Rivers CS; Janakiraman V; Wang W; Kinch LN; Grishin NV; Haverty PM; Chow B; Gehring JS; Reeder J; Pau G; Wu TD; Margulis V; Lotan Y; Sagalowsky A; Pedrosa I; de Sauvage FJ; Brugarolas J; Seshagiri S
Nat Genet; 2015 Jan; 47(1):13-21. PubMed ID: 25401301
[TBL] [Abstract][Full Text] [Related]
22. Mutations in renal cell carcinoma.
D'Avella C; Abbosh P; Pal SK; Geynisman DM
Urol Oncol; 2020 Oct; 38(10):763-773. PubMed ID: 30478013
[TBL] [Abstract][Full Text] [Related]
23. Frequency and Nature of Genomic Alterations in ERBB2-Altered Urothelial Bladder Cancer.
Leary JB; Enright T; Bakaloudi DR; Basnet A; Bratslavsky G; Jacob J; Spiess PE; Li R; Necchi A; Kamat AM; Pavlick DC; Danziger N; Huang RSP; Lin DI; Cheng L; Ross J; Talukder R; Grivas P
Target Oncol; 2024 May; 19(3):447-458. PubMed ID: 38570422
[TBL] [Abstract][Full Text] [Related]
24. Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape.
Wang Z; Kim TB; Peng B; Karam J; Creighton C; Joon A; Kawakami F; Trevisan P; Jonasch E; Chow CW; Canales JR; Tamboli P; Tannir N; Wood C; Monzon F; Baggerly K; Varella-Garcia M; Czerniak B; Wistuba I; Mills G; Shaw K; Chen K; Sircar K
Clin Cancer Res; 2017 Nov; 23(21):6686-6696. PubMed ID: 28710314
[No Abstract] [Full Text] [Related]
25. BAP1-Mutated Clear Cell Renal Cell Carcinoma.
Gallan AJ; Parilla M; Segal J; Ritterhouse L; Antic T
Am J Clin Pathol; 2021 Apr; 155(5):718-728. PubMed ID: 33210135
[TBL] [Abstract][Full Text] [Related]
26. Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer.
Sivapiragasam A; Ashok Kumar P; Sokol ES; Albacker LA; Killian JK; Ramkissoon SH; Huang RSP; Severson EA; Brown CA; Danziger N; McGregor K; Ross JS
Cancer Med; 2021 Jan; 10(1):53-61. PubMed ID: 33314633
[TBL] [Abstract][Full Text] [Related]
27. Sporadic oncocytic tumors with features intermediate between oncocytoma and chromophobe renal cell carcinoma: comprehensive clinicopathological and genomic profiling.
Liu YJ; Ussakli C; Antic T; Liu Y; Wu Y; True L; Tretiakova MS
Hum Pathol; 2020 Oct; 104():18-29. PubMed ID: 32673684
[TBL] [Abstract][Full Text] [Related]
28. PBRM1 and BAP1 as novel targets for renal cell carcinoma.
Brugarolas J
Cancer J; 2013; 19(4):324-32. PubMed ID: 23867514
[TBL] [Abstract][Full Text] [Related]
29. Genomic Features of Metastatic Testicular Sex Cord Stromal Tumors.
Necchi A; Bratslavsky G; Shapiro O; Elvin JA; Vergilio JA; Killian JK; Ngo N; Ramkissoon S; Severson E; Hemmerich AC; Ali SM; Chung JH; Reddy P; Miller VA; Schrock AB; Gay LM; Ross JS; Jacob JM
Eur Urol Focus; 2019 Sep; 5(5):748-755. PubMed ID: 31147264
[TBL] [Abstract][Full Text] [Related]
30. Clinically Advanced Pheochromocytomas and Paragangliomas: A Comprehensive Genomic Profiling Study.
Bratslavsky G; Sokol ES; Daneshvar M; Necchi A; Shapiro O; Jacob J; Liu N; Sanford TS; Pinkhasov R; Goldberg H; Killian JK; Ramkissoon S; Severson EA; Huang RSP; Danziger N; Mollapour M; Ross JS; Pacak K
Cancers (Basel); 2021 Jul; 13(13):. PubMed ID: 34282751
[TBL] [Abstract][Full Text] [Related]
31. Genomic profiling of renal cell carcinoma in patients with end-stage renal disease.
Inoue T; Matsuura K; Yoshimoto T; Nguyen LT; Tsukamoto Y; Nakada C; Hijiya N; Narimatsu T; Nomura T; Sato F; Nagashima Y; Kashima K; Hatakeyama S; Ohyama C; Numakura K; Habuchi T; Nakagawa M; Seto M; Mimata H; Moriyama M
Cancer Sci; 2012 Mar; 103(3):569-76. PubMed ID: 22145865
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathological and survival analysis of clinically advanced papillary and chromophobe renal cell carcinoma.
Kaldany A; Paulucci DJ; Kannappan M; Beksac AT; Anastos H; Okhawere K; Sfakianos JP; Badani KK
Urol Oncol; 2019 Oct; 37(10):727-734. PubMed ID: 31174958
[TBL] [Abstract][Full Text] [Related]
33. TCEB1-mutated renal cell carcinoma: a distinct genomic and morphological subtype.
Hakimi AA; Tickoo SK; Jacobsen A; Sarungbam J; Sfakianos JP; Sato Y; Morikawa T; Kume H; Fukayama M; Homma Y; Chen YB; Sankin A; Mano R; Coleman JA; Russo P; Ogawa S; Sander C; Hsieh JJ; Reuter VE
Mod Pathol; 2015 Jun; 28(6):845-853. PubMed ID: 25676555
[TBL] [Abstract][Full Text] [Related]
34. Differential Expression of PD-L1 Between Sporadic and VHL-Associated Hereditary Clear-Cell Renal Cell Carcinoma and Its Correlation With Clinicopathological Features.
Hong B; Cai L; Wang J; Liu S; Zhou J; Ma K; Zhang J; Zhou B; Peng X; Zhang N; Gong K
Clin Genitourin Cancer; 2019 Apr; 17(2):97-104.e1. PubMed ID: 30522901
[TBL] [Abstract][Full Text] [Related]
35. Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma.
Bihr S; Ohashi R; Moore AL; Rüschoff JH; Beisel C; Hermanns T; Mischo A; Corrò C; Beyer J; Beerenwinkel N; Moch H; Schraml P
Neoplasia; 2019 Feb; 21(2):247-256. PubMed ID: 30660076
[TBL] [Abstract][Full Text] [Related]
36. Genomic profiling of the genes on chromosome 3p in sporadic clear cell renal cell carcinoma.
Togo Y; Yoshikawa Y; Suzuki T; Nakano Y; Kanematsu A; Zozumi M; Nojima M; Hirota S; Yamamoto S; Hashimoto-Tamaoki T
Int J Oncol; 2016 Apr; 48(4):1571-80. PubMed ID: 26891804
[TBL] [Abstract][Full Text] [Related]
37. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.
Ricketts CJ; De Cubas AA; Fan H; Smith CC; Lang M; Reznik E; Bowlby R; Gibb EA; Akbani R; Beroukhim R; Bottaro DP; Choueiri TK; Gibbs RA; Godwin AK; Haake S; Hakimi AA; Henske EP; Hsieh JJ; Ho TH; Kanchi RS; Krishnan B; Kwiatkowski DJ; Liu W; Merino MJ; Mills GB; Myers J; Nickerson ML; Reuter VE; Schmidt LS; Shelley CS; Shen H; Shuch B; Signoretti S; Srinivasan R; Tamboli P; Thomas G; Vincent BG; Vocke CD; Wheeler DA; Yang L; Kim WY; Robertson AG; ; Spellman PT; Rathmell WK; Linehan WM
Cell Rep; 2018 Apr; 23(1):313-326.e5. PubMed ID: 29617669
[TBL] [Abstract][Full Text] [Related]
38. Advanced Squamous Cell Carcinomas of the Pelvic and Perineal Region: A Comprehensive Genomic Profiling Study.
Necchi A; Spiess PE; Bandini M; Basile G; Grivas P; Bratslavsky G; Jacob J; Danziger N; Lin D; Decker B; Sokol ES; Huang RSP; Kulkarni SB; Ross JS
Oncologist; 2022 Dec; 27(12):1016-1024. PubMed ID: 35881043
[TBL] [Abstract][Full Text] [Related]
39. JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management.
Gupta S; Cheville JC; Jungbluth AA; Zhang Y; Zhang L; Chen YB; Tickoo SK; Fine SW; Gopalan A; Al-Ahmadie HA; Sirintrapun SJ; Blum KA; Lohse CM; Hakimi AA; Thompson RH; Leibovich BC; Berger MF; Arcila ME; Ross DS; Ladanyi M; Antonescu CR; Reuter VE
Mod Pathol; 2019 Sep; 32(9):1344-1358. PubMed ID: 30996253
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations.
Ross JS; Wang K; Khaira D; Ali SM; Fisher HA; Mian B; Nazeer T; Elvin JA; Palma N; Yelensky R; Lipson D; Miller VA; Stephens PJ; Subbiah V; Pal SK
Cancer; 2016 Mar; 122(5):702-11. PubMed ID: 26651075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
